Alexander Weingarten, MD
Interventional Pain Medicine · Syosset, NYNPI 1558353078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,149 of the $42,520 with a category attached, or 61.5%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.0%. Reporting peaked in 2019 at $15,396 and has fallen 68.7% since, to $4,812 in 2025. Among interventional pain medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,888 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$7K
- West Therapeutics Development, LLC$5K
- Collegium Pharmaceutical, Inc.$3K
- AbbVie$3K
- Scilex Pharmaceuticals Inc.$2K
- Regeneron$2K
- plus $20K from 54 others
What the payments were for
- Consulting fees$7,99019%
- Speaking & faculty fees$6,75016%
- Travel & lodging$1,5894%
- Food & beverage$26,14961%
- Education$420%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucemyra/Lofexidine$6,444
- Lazanda$5,000
- NURTEC ODT$1,200
- Roxybond$1,000
- Prolate$878
- BELBUCA$750
- Nalocet$350
- UBRELVY$226
- BOTOX$161
- QULIPTA$120
- Senza Spinal Cord Stimulation System$117
- PRIALT$115
How this compares
$42,520 in reported general payments places this provider in the 90th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide ErBudesonide | 172 | $529,737 |
| OxycontinOxycodone Hcl | 247 | $322,401 |
| Levorphanol Tartrate | 119 | $308,055 |
| Nucynta ErTapentadol Hcl | 250 | $275,935 |
| Diclofenac Sodium | 217 | $185,179 |
| Diclofenac Potassium | 458 | $138,643 |
| Xtampza ErOxycodone Myristate | 132 | $117,227 |
| RoxybondOxycodone Hcl | 59 | $97,161 |
| RelistorMethylnaltrexone Bromide | 32 | $97,109 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 709 | $94,952 |
| BelbucaBuprenorphine Hcl | 98 | $72,520 |
| Nurtec OdtRimegepant Sulfate | 35 | $66,132 |
| PercocetOxycodone Hcl/Acetaminophen | 16 | $64,593 |
| NucyntaTapentadol Hcl | 56 | $62,011 |
| ZtlidoLidocaine | 101 | $61,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca, Nucynta | $3,229 | $527,693536 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $389 | $308,055119 claims |
| Protega Pharmaceutials IncRoxybond | $1,360 | $97,16159 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $682 | $97,10932 claims |
| PfizerNurtec Odt, Lyrica | $929 | $94,35668 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $2,336 | $61,290101 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $453 | $58,54262 claims |
| Redhill Biopharma Inc.Movantik | $962 | $55,968138 claims |
| Forte Bio-pharma LLCProlate | $959 | $51,88133 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone | $33 | $43,907207 claims |
| AbbVieUbrelvy, Linzess | $3,078 | $41,34842 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,459 | $20,61135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in Syosset
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Jafar SiddiquiWilliamsville$45K
- Marco PappagalloNew York$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.